Last updated 2024-12-22 04:00:38 (EST)

Fundamental Analysis

By analyzing seasonally adjusted quarterly revenue, one can gauge the trend of stock. However, please note that stock prices can sometimes lead fundamental data, so it should be accompanied by other leading indicators for better judgment.

Quarterly Revenue Trend tooltip

Quarter-over-Quarter Growth Rate
of Seasonally Adjusted Quarterly Revenue

324.8%


As of 2024-09-30

Basic Information

Basic information of individual stocks, as well as their respective sectors and industries.

Company Introduction

Business Overview

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Industry

Sector
Healthcare
Industry
Biotechnology

Disclaimer

1. The information provided is for reference only and does not constitute any guarantee of profits or specific stock and price point recommendations.

2. The information is not complete; for comprehensive data, please refer to the relevant websites.

3. All stock market data analyses are subject to survivorship bias.

warning